Satellos Bioscience Inc.
MSCL.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.74M | -21.56M | -20.55M | -20.99M | -17.02M |
| Total Depreciation and Amortization | 11.80K | 13.80K | 14.80K | 7.70K | 7.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.73M | 3.55M | 2.75M | 5.44M | 1.64M |
| Change in Net Operating Assets | -2.00M | -2.43M | -799.20K | 685.00K | 738.50K |
| Cash from Operations | -21.00M | -20.43M | -18.59M | -14.86M | -14.63M |
| Capital Expenditure | -3.00K | -3.00K | -4.00K | -4.70K | -12.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.16M | 6.67M | 5.30M | 727.30K | -12.25M |
| Cash from Investing | 13.15M | 6.67M | 5.30M | 722.60K | -12.27M |
| Total Debt Issued | -- | -- | -- | 140.00K | 139.00K |
| Total Debt Repaid | -- | -- | -- | -237.00K | -2.62M |
| Issuance of Common Stock | 45.01M | 43.63M | 43.63M | 2.92M | 2.70M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.85M | 9.85M | 9.85M | -3.19M | -2.83M |
| Cash from Financing | 39.59M | 38.21M | 38.21M | -270.00K | -1.94M |
| Foreign Exchange rate Adjustments | 816.40K | 86.40K | -32.60K | -1.47M | -336.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.57M | 24.54M | 24.89M | -15.88M | -29.17M |